Tenderwize
Zurück zur Suche

Open-house rebate agreements for Xipamid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 493 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Xipamid, ATC C03BA10

58/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

58 / 100

Komplexität

42 / 100

Risikofaktoren

The notice says the model is open-house and not subject to ordinary procurement selection logic, which may affect legal...

Documents must be submitted through the DTVP communication area, not the offer area; paper originals must be in duplica...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive pharmaceutical rebate agreements for the active substance Xipamid (ATC C03BA10).
  • Open-house model with identical, pre-set contract terms and no individual negotiation.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Xipamid (ATC C03BA10) led by AOK Bayern. It is not a competitive award procedure in the usual sense: all interested pharmaceutical companies that meet the stated eligibility condition can join on identical, non-negotiable terms. The contract period runs from 01.03.2026 to 29.02.2028, with contract entry possible until 03.01.2028. Submission is via DTVP electronic portal with a qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents must be submitted with German translation.

Risiken

The notice says the model is open-house and not subject to ordinary procurement selection logic, which may affect legal...

Documents must be submitted through the DTVP communication area, not the offer area; paper originals must be in duplica...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract and annex 'Determination of the contract products' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreements for Xipamid

Open-house supply arrangement for pharmaceutical rebate agreements concerning Xipamid (ATC C03BA10). The lot is described as a non-exclusive, identical, non-negotiable contract model for all eligible pharmaceutical companies. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Feb 2026 - Feb 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 03, 2028

Vergabedetails

Veröffentlichungsdatum
13 Jan 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
23964-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30